July 2011 Archives : Discussions About IMF Web Site Content
- WHAT IS MULTIPLE MYELOMA?
- Autologous Bone Marrow And Stem Cell Transplantation For Multiple Myeloma, part 1
- WHAT IS MULTIPLE MYELOMA?
- Applying For An International Myeloma Foundation Research Grant
- Myeloma Minute - March 14, 2006
- Sydney 2005: Combination of Tipifarnib & Bortezomib Results in Synergistic MM Cell death...
- ASH 2009: Edward Agura
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study - Sydney 2005: Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor
- Sydney 2005: CHIR-258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Tx of t(4;14) MM
- Sydney 2005:
Tumor Immune Interactions in Myeloma
- Myeloma Minute - March 14, 2006
- Sydney 2005: Combination of Tipifarnib & Bortezomib Results in Synergistic MM Cell death...
- ASH 2009: Edward Agura
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study - Sydney 2005: Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor
- Sydney 2005: CHIR-258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Tx of t(4;14) MM
- Sydney 2005:
Tumor Immune Interactions in Myeloma - Myeloma Today Spring 2007 in PDF format
- Dr. Sher - Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
- ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials - La Terapia